CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 374 enrolled
Drug / intervention
Prolapse Repairprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01945580
NCT01945580N/ACompleted
CompareCT.gov

A Prospective, Non-Randomized, Parallel Cohort, Multi-Center Study of Xenform vs. Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse

Boston Scientific Corporation·interventional·Posted Sep 18, 2013·Updated Apr 14, 2021

In Brief

A clinical study evaluating Prolapse Repair for Pelvic Organ Prolapse. Completed, enrolled 374 participants across 25 sites.

Detailed Summary

To compare transvaginal repair with a biologic graft to traditional native tissue repair in women surgically treated for anterior and/or apical pelvic organ prolapse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPelvic Organ Prolapse
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 18, 2013
Enrollment StartFeb 10, 2014
Primary CompletionFeb 12, 2020
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 12.8 years ago

Interventions

Prolapse Repairprocedure

Transvaginal anterior/apical pelvic organ prolapse repair